Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
The complexity of operating on a one-year-old are many with the organs being tiny, fragile
Subscribe To Our Newsletter & Stay Updated
